Evidence map›Paper›PMID 41369171›Full record

ArticleOncoimmunology2025

Serum Arginase-1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness.

Matthias Brand, Juraj Adamik, Hong Wang, Sharon E Sember, Jennifer L Muzzio, Mary J Buffo, Cindy A Sander, John M Kirkwood, Robert L Ferris, Lisa H Butterfield and 1 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthias BrandUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0009-0007-9722-8771
Juraj AdamikParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Hong WangDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA.
Sharon E SemberUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Jennifer L MuzzioUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Mary J BuffoUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Cindy A SanderUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
John M KirkwoodUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-3570-4476
Robert L FerrisUNC Lineberger Comprehensive Cancer Center, UNC Health Care System, Chapel Hill, NC, USA.ORCID 0000-0001-6605-2071
Lisa H ButterfieldUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-3439-9844
Lazar VujanovicUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0003-1729-8619

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA121973
6 · The paper itself

Abstract

While recent advances in immuno-oncology have revolutionized cancer therapy, only a subset patients benefit from these treatments and achieve durable clinical responses. Biomarker-guided identification of patients likely to respond to immunotherapy could enable more effective management of various malignancies. To explore this, we took advantage of a Phase I trial evaluating the efficacy of antigen-engineered dendritic cell (DC) vaccine, administered either as monotherapy or in combination with high-dose interferon-α2b, in promoting anti-tumor immunity in melanoma patients. Liquid biopsies, including serum and peripheral blood mononuclear cells, and tumor biopsies were previously analyzed for predictive markers using Luminex, NanoString gene expression profiling and flow cytometry. Here,

Indexed as

ArginaseBiomarkers, TumorMelanomaMyeloid CellsAdultAgedCancer VaccinesDendritic CellsFemaleHumansImmunotherapyMaleMiddle AgedARG1 protein, humanArginaseBiomarkers, TumorCancer Vaccinesarginase−1biomarkersdendritic cellsimmunotherapyliquid biopsiesMelanomavaccines

Identifiers

PMID41369171
PMCPMC12698054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.